Does Diamox have a significant effect on intraocular pressure after a Lucentis injection therapy in Glaucoma patients?
Not Applicable
Completed
- Conditions
- GlaucomaEar, Nose and Throat
- Registration Number
- ISRCTN87077451
- Lead Sponsor
- York Teaching Hospital NHS Foundation Trust (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
1. Patients with neovascular (wet) AMD requiring Lucentis injections
2. Glaucoma
3. Glaucoma suspect
4. Written informed consent
5. Baseline pre-injection IOP of less than 30mmHg
Exclusion Criteria
1. Baseline pre-injection IOP of 30 mmHg or higher
2. Unable to give written informed consent
3. Known allergy to sulphur/sulphonamide containing drugs or acetazolamide
4. 18 years or younger
5. Marked kidney or liver disease/dysfunction
6. Supra-renal gland failure
7. Hyperchloremic acidosis
8. Hepatic cirrhosis
9. Pregnancy / [Pre]-menopausal
10. Concomitant use of other oral carbonic anhydrase inhibitors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean IOP (intraocular pressure) change from baseline (T-B) immediately after injection (T0), 5 minutes (T5), 10 minutes (T10) and 30 minutes (T30). A handheld tonometer will be used to measure the IOP.
- Secondary Outcome Measures
Name Time Method o secondary outcome measures